Clinical Research on Accuray’s CyberKnife® and TomoTherapy® Systems to Be Presented at Key Industry Event for Medical Physicists
SUNNYVALE, Calif., July 29, 2012 /PRNewswire/ — Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that more than 70 studies on the clinical use of the CyberKnife Robotic Radiosurgery® System and the TomoTherapy® System will be presented at the 54(th) Annual Meeting of the American Association of Physicists in Medicine (AAPM) taking place in Charlotte, N.C. July 29 – August 2, 2012. The Annual AAPM Meeting usually draws about 4,000 attendees.
Studies from leading centers will showcase both the CyberKnife System and the TomoTherapy System. The presentations continue to validate Accuray’s standard-setting treatment planning and delivery techniques, accurate patient setup and intrafraction motion tracking, as well as quality assurance practices for the industry’s premier, fully-integrated radiosurgery and intensity-modulated radiotherapy platforms. Of note are studies that emphasize the benefits of each technology in demanding clinical situations. Key examples are the TomoTherapy System’s unmatched ability to provide organ sparing and dose homogeneity in hippocampal-avoidance whole brain radiotherapy and the CyberKnife System’s ability to maintain continual tracking accuracy during treatment of liver tumors undergoing a large degree of respiratory motion.
Accuray will also host a symposium on Monday, July 30, 2012 from 12:30 p.m. EDT – 1:30 p.m. EDT at The Westin Charlotte Hotel. The session will focus on Accuray’s new VoLO(TM) technology for the TomoTherapy System, a treatment planning platform that leverages advanced parallel processing technology and a new dose calculation algorithm to increase clinical efficiency, throughput and flexibility in developing even the most complex treatment plans. In addition, the symposium will highlight TomoTherapy’s new Dose Control System, improving system stability during and between treatments.
“Medical physicists play a vital role in the radiation therapy field, ensuring patient safety and treatment quality, two areas to which Accuray is strongly dedicated,” said Euan S. Thomson, Ph.D., Accuray president and chief executive officer.”We are pleased by the quantity and quality of clinical research being presented. This work adds to the growing body of scientific evidence validating the safe and effective use of our products for an expanding range of clinical indications.”
Accuray will be exhibiting at booth #909. Presenters include Robert Staton, Medical Physicist, MD Anderson Orlando who will be presenting on his experience with the TomoTherapy Dose Control System and Kenneth Ruchala, Ph.D., Accuray Incorporated who will be presenting information on the Non-Voxel Broad Beam algorithm for a GPU-based dose calculator. Additionally, Accuray will host demonstrations of its VoLO technology for the TomoTherapy System at the booth.
The TomoTherapy System is a fully integrated 3D image guided intensity modulated radiation therapy system that provides patients with the most accurate, personalized cancer care. The technology uses daily computed tomography (CT) imaging to identify the exact position of the tumor on each day of treatment, enabling clinicians to customize treatment for each patient, minimize radiation exposure to healthy tissue and reduce side effects. The TomoTherapy System uses a radiation beam that continually rotates in 360 degree arcs about the patient, meaning that treatments can be delivered continuously to the tumor from every angle.
The CyberKnife System is the first and only robotic radiosurgery system that provides a pain-free, non-invasive treatment option for patients who are looking for an alternative to surgery or who have an inoperable or surgically complex tumor. CyberKnife treatment is typically completed in just one to five days, instead of the 40 or more treatment sessions typically required with conventional radiation therapy. The CyberKnife System offers unique capabilities that automatically account for the natural motion of the tumor throughout treatment. The ability to manage motion in real time helps ensure that radiation is delivered only to the tumor while sparing healthy tissue and critical structures.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 635 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to reduced radiation exposure, accuracy, clinical efficiency, clinical applications, and clinical benefits. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading “Risk Factors” in the Company’s report on Form 10-K for fiscal year 2011, and its reports on Form 10-Q for the first, second and third quarters of fiscal 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D.
SOURCE Accuray Incorporated